Selective serotonin reuptake inhibitor (SSRI) modulation of striatal dopamine measured with [11C]-raclopride and positron emission tomography.
Selective serotonin reuptake inhibitor (SSRI) modulation of striatal dopamine measured with [11C]-raclopride and positron emission tomography.
复制标题
使用[11C]-雷氯必利和正电子发射断层扫描测量纹状体多巴胺的选择性血清素再摄取抑制剂（SSRI）调节。
DOI：
10.1002/syn.20574
复制
发表时间：
2009
期刊：
影响因子：
--
通讯作者：
Eidelberg,David
中科院分区：
文献类型：
--
作者：
Smith,GwennS;Ma,Yilong;Dhawan,Vijay;Chaly,Thomas;Eidelberg,David
在几项研究中，使用正电子发射断层扫描（PET）和放射性示踪剂[11 C]-雷氯必利作为人体受试者纹状体多巴胺5-羟色胺调节的体内成像方法，测量了5-羟色胺浓度药理学增加对纹状体多巴胺（D2）受体可用性的影响。这些研究表明，血清素浓度的急性增加导致纹状体D2受体可用性降低。目前的研究是为了衡量一个更有选择性的多巴胺能药物相比，以前的研究，5-羟色胺再摄取抑制剂，西酞普兰，对纹状体D2受体的可用性的影响。12名健康对照受试者在静脉注射生理盐水（扫描1）和西酞普兰（扫描2，40 mg，静脉注射）后的同一天进行两次PET扫描。使用小脑作为输入函数，采用图形分析方法分析[11 C]-雷氯必利数据。测定西酞普兰、皮质醇和催乳素的血浆水平。西酞普兰浓度在输注结束时（EOI）达到峰值，并在输注后30 min至3 h保持相对一致。皮质醇和催乳素浓度的增加，观察到从EOI，直到EOI后60分钟。在西酞普兰输注后观察到纹状体D2受体可用性显著降低（-5%），推测是由于内源性多巴胺浓度增加。总之，静脉注射选择性5-羟色胺再吸收抑制剂西酞普兰可适度降低纹状体D2受体的可用性，这与使用药理学选择性较低的5-羟色胺能药物的其他人体[11 C]-雷氯必利研究一致。Synapse 63：1-6，2009.© 2008 Wiley利斯公司
The effect of a pharmacologic increase in serotonin concentrations on striatal dopamine (D2) receptor availability has been measured in several studies using positron emission tomography (PET) and the radiotracer [11C]‐raclopride as a method for the in vivo imaging of serotonin modulation of striatal dopamine in human subjects. These studies have shown that an acute increase in serotonin concentrations produced a decrease in striatal D2 receptor availability. The current study was undertaken to measure the effects of a more pharmacologically selective serotonergic agent compared to previous studies, the serotonin reuptake inhibitor, citalopram, on striatal D2 receptor availability. Twelve healthy control subjects underwent two PET scans performed on the same day following i.v. administration of saline (Scan 1) and citalopram (Scan 2, 40 mg, i.v.). The [11C]‐raclopride data were analyzed with a graphical analysis method using the cerebellum as the input function. Plasma levels of citalopram, cortisol, and prolactin were measured. The citalopram concentrations peaked at the end of infusion (EOI) and remained relatively consistent from 30 min to 3 h postinfusion. An increase in cortisol and prolactin concentrations was observed from the EOI until 60 min after the EOI. A significant decrease in striatal D2 receptor availability was observed after citalopram infusion (−5%), presumably due to an increase in endogenous dopamine concentrations. In summary, i.v. administration of the selective serotonin reuptake inhibitor, citalopram, produced modest reductions in striatal D2 receptor availability, consistent with other human [11C]‐raclopride studies using less pharmacologically selective serotonergic agents. Synapse 63:1–6, 2009. © 2008 Wiley‐Liss, Inc.